Bioinfra Life Sciences (CEO Deokyun Lee) announced on the 12th that it has recently succeeded in developing a smart drug delivery platform technology that responds to external stimuli, a drug delivery technology gaining attention.
Recently, various studies on targeted drug delivery technology aimed at delivering drugs only to specific organs or tissues within the human body have been actively conducted. In particular, there is an increasing demand for the development of multifunctional drug delivery systems using convergence technologies. This technology primarily has the advantage of reducing the amount of drug administered for treatment and thereby decreasing concerns about side effects.
Bioinfra Life Sciences has conducted years of research from formulation studies to load various poorly soluble substances into drug delivery systems to the development of external stimulus-responsive drug delivery systems to enhance targeted delivery efficiency. Recently, as a result of long-term research, the company succeeded in developing an external stimulus-responsive smart drug delivery system with high sensitivity to ultrasound energy.
The developed ultrasound-responsive drug delivery system has structural characteristics that can simultaneously contain materials sensitive to ultrasound energy and therapeutic agents for disease treatment. Its outer wall is PEGylated, allowing stable circulation within the human body, and it is designed with a manufacturing protocol capable of mass production.
Additionally, Bioinfra Life Sciences possesses ultrasound signal technology to effectively activate this external stimulus-responsive drug delivery system at the desired location.
The Bioinfra Life Sciences research team recently succeeded in verifying effective anticancer drug delivery and targeted anticancer effects in breast cancer cell lines by loading the anticancer drug doxorubicin onto the developed drug delivery platform.
Excellent research results derived during the technology verification process were published on the 3rd in the SCIE-level international journal Current Drug Delivery. Intellectual property rights related to the drug delivery system manufacturing method and structure obtained during this process were secured through a new patent application last year.
Furthermore, as part of the technology commercialization process, the company is conducting in-vivo animal experiments for pharmacokinetics (PK), pharmacodynamics (PD), and quantification of drug targeting efficiency of the developed drug delivery system, and based on these results, joint clinical trials with leading domestic and international pharmaceutical companies are planned.
Deokyun Lee, CEO of Bioinfra Life Sciences, stated, “The targeted drug delivery technology using the ultrasound-responsive drug delivery system developed by our company has a wide range of applications, including breast, pancreas, gastrointestinal tract, liver, and brain, where ultrasound irradiation is possible. In particular, it can be applied diversely to formulations with different characteristics, and we expect it to be utilized in the future for various intractable diseases, including anticancer drugs.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
